Literature DB >> 24764668

Non-transmissible Sendai virus vector encoding c-myc suppressor FBP-interacting repressor for cancer therapy.

Kazuyuki Matsushita1, Hideaki Shimada1, Yasuji Ueda1, Makoto Inoue1, Mamoru Hasegawa1, Takeshi Tomonaga1, Hisahiro Matsubara1, Fumio Nomura1.   

Abstract

AIM: To investigate a novel therapeutic strategy to target and suppress c-myc in human cancers using far up stream element (FUSE)-binding protein-interacting repressor (FIR).
METHODS: Endogenous c-Myc suppression and apoptosis induction by a transient FIR-expressing vector was examined in vivo via a HA-tagged FIR (HA-FIR) expression vector. A fusion gene-deficient, non-transmissible, Sendai virus (SeV) vector encoding FIR cDNA, SeV/dF/FIR, was prepared. SeV/dF/FIR was examined for its gene transduction efficiency, viral dose dependency of antitumor effect and apoptosis induction in HeLa (cervical squamous cell carcinoma) cells and SW480 (colon adenocarcinoma) cells. Antitumor efficacy in a mouse xenograft model was also examined. The molecular mechanism of the anti-tumor effect and c-Myc suppression by SeV/dF/FIR was examined using Spliceostatin A (SSA), a SAP155 inhibitor, or SAP155 siRNA which induce c-Myc by increasing FIR∆exon2 in HeLa cells.
RESULTS: FIR was found to repress c-myc transcription and in turn the overexpression of FIR drove apoptosis through c-myc suppression. Thus, FIR expressing vectors are potentially applicable for cancer therapy. FIR is alternatively spliced by SAP155 in cancer cells lacking the transcriptional repression domain within exon 2 (FIR∆exon2), counteracting FIR for c-Myc protein expression. Furthermore, FIR forms a complex with SAP155 and inhibits mutual well-established functions. Thus, both the valuable effects and side effects of exogenous FIR stimuli should be tested for future clinical application. SeV/dF/FIR, a cytoplasmic RNA virus, was successfully prepared and showed highly efficient gene transduction in in vivo experiments. Furthermore, in nude mouse tumor xenograft models, SeV/dF/FIR displayed high antitumor efficiency against human cancer cells. SeV/dF/FIR suppressed SSA-activated c-Myc. SAP155 siRNA, potentially produces FIR∆exon2, and led to c-Myc overexpression with phosphorylation at Ser62. HA-FIR suppressed endogenous c-Myc expression and induced apoptosis in HeLa and SW480 cells. A c-myc transcriptional suppressor FIR expressing SeV/dF/FIR showed high gene transduction efficiency with significant antitumor effects and apoptosis induction in HeLa and SW480 cells.
CONCLUSION: SeV/dF/FIR showed strong tumor growth suppression with no significant side effects in an animal xenograft model, thus SeV/dF/FIR is potentially applicable for future clinical cancer treatment.

Entities:  

Keywords:  Cancer gene therapy; Far up stream element-binding protein-interacting repressor; Sendai virus vector; c-myc suppressor

Mesh:

Substances:

Year:  2014        PMID: 24764668      PMCID: PMC3989966          DOI: 10.3748/wjg.v20.i15.4316

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  37 in total

1.  PUF60: a novel U2AF65-related splicing activity.

Authors:  P S Page-McCaw; K Amonlirdviman; P A Sharp
Journal:  RNA       Date:  1999-12       Impact factor: 4.942

2.  A far upstream element stimulates c-myc expression in undifferentiated leukemia cells.

Authors:  M I Avigan; B Strober; D Levens
Journal:  J Biol Chem       Date:  1990-10-25       Impact factor: 5.157

3.  Defective interplay of activators and repressors with TFIH in xeroderma pigmentosum.

Authors:  J Liu; S Akoulitchev; A Weber; H Ge; S Chuikov; D Libutti; X W Wang; J W Conaway; C C Harris; R C Conaway; D Reinberg; D Levens
Journal:  Cell       Date:  2001-02-09       Impact factor: 41.582

4.  Efficient gene transfer to airway epithelium using recombinant Sendai virus.

Authors:  Y Yonemitsu; C Kitson; S Ferrari; R Farley; U Griesenbach; D Judd; R Steel; P Scheid; J Zhu; P K Jeffery; A Kato; M K Hasan; Y Nagai; I Masaki; M Fukumura; M Hasegawa; D M Geddes; E W Alton
Journal:  Nat Biotechnol       Date:  2000-09       Impact factor: 54.908

5.  Reversible tumorigenesis by MYC in hematopoietic lineages.

Authors:  D W Felsher; J M Bishop
Journal:  Mol Cell       Date:  1999-08       Impact factor: 17.970

6.  Synergistic effect of non-transmissible Sendai virus vector encoding the c-myc suppressor FUSE-binding protein-interacting repressor plus cisplatin in the treatment of malignant pleural mesothelioma.

Authors:  Atsushi Kitamura; Kazuyuki Matsushita; Yuichi Takiguchi; Hideaki Shimada; Yuji Tada; Makako Yamanaka; Kenzo Hiroshima; Masatoshi Tagawa; Takeshi Tomonaga; Hisahiro Matsubara; Makoto Inoue; Mamoru Hasegawa; Yasunori Sato; David Levens; Koichiro Tatsumi; Fumio Nomura
Journal:  Cancer Sci       Date:  2011-05-09       Impact factor: 6.716

7.  Efficient eradication of hormone-resistant human prostate cancers by inactivated Sendai virus particle.

Authors:  Yoshifumi Kawaguchi; Yasuhide Miyamoto; Takehiro Inoue; Yasufumi Kaneda
Journal:  Int J Cancer       Date:  2009-05-15       Impact factor: 7.396

8.  Interactions between SAP155 and FUSE-binding protein-interacting repressor bridges c-Myc and P27Kip1 expression.

Authors:  Kazuyuki Matsushita; Mai Tamura; Nobuko Tanaka; Takeshi Tomonaga; Hisahiro Matsubara; Hideaki Shimada; David Levens; Liusheng He; Juhong Liu; Minoru Yoshida; Fumio Nomura
Journal:  Mol Cancer Res       Date:  2013-04-17       Impact factor: 5.852

9.  Postischemic administration of Sendai virus vector carrying neurotrophic factor genes prevents delayed neuronal death in gerbils.

Authors:  M Shirakura; M Inoue; S Fujikawa; K Washizawa; S Komaba; M Maeda; K Watabe; Y Yoshikawa; M Hasegawa
Journal:  Gene Ther       Date:  2004-05       Impact factor: 5.250

10.  Dimerization and protein binding specificity of the U2AF homology motif of the splicing factor Puf60.

Authors:  Lorenzo Corsini; Michael Hothorn; Gunter Stier; Vladimir Rybin; Klaus Scheffzek; Toby J Gibson; Michael Sattler
Journal:  J Biol Chem       Date:  2008-10-29       Impact factor: 5.157

View more
  7 in total

Review 1.  Alternative splicing of DNA damage response genes and gastrointestinal cancers.

Authors:  Bahityar Rahmutulla; Kazuyuki Matsushita; Fumio Nomura
Journal:  World J Gastroenterol       Date:  2014-12-14       Impact factor: 5.742

2.  Sendai virus-mediated gene transfer of the c-myc suppressor far-upstream element-binding protein-interacting repressor suppresses head and neck cancer.

Authors:  N Tanaka; K Araki; D Mizokami; Y Miyagawa; T Yamashita; M Tomifuji; Y Ueda; M Inoue; K Matsushita; F Nomura; H Shimada; A Shiotani
Journal:  Gene Ther       Date:  2015-01-15       Impact factor: 5.250

Review 3.  Gene Therapy for Malignant and Benign Gynaecological Disorders: A Systematic Review of an Emerging Success Story.

Authors:  Ekati Drakopoulou; Nicholas P Anagnou; Kalliopi I Pappa
Journal:  Cancers (Basel)       Date:  2022-06-30       Impact factor: 6.575

4.  Adenovirus-mediated FIR demonstrated TP53-independent cell-killing effect and enhanced antitumor activity of carbon-ion beams.

Authors:  M Kano; K Matsushita; B Rahmutulla; S Yamada; H Shimada; S Kubo; T Hiwasa; H Matsubara; F Nomura
Journal:  Gene Ther       Date:  2015-08-04       Impact factor: 5.250

5.  Haploinsufficiency of the c-myc transcriptional repressor FIR, as a dominant negative-alternative splicing model, promoted p53-dependent T-cell acute lymphoblastic leukemia progression by activating Notch1.

Authors:  Kazuyuki Matsushita; Kouichi Kitamura; Bahityar Rahmutulla; Nobuko Tanaka; Takayuki Ishige; Mamoru Satoh; Tyuji Hoshino; Satoru Miyagi; Takeshi Mori; Sakae Itoga; Hideaki Shimada; Takeshi Tomonaga; Minoru Kito; Yaeko Nakajima-Takagi; Shuji Kubo; Chiaki Nakaseko; Masahiko Hatano; Takashi Miki; Masafumi Matsuo; Masaki Fukuyo; Atsushi Kaneda; Atsushi Iwama; Fumio Nomura
Journal:  Oncotarget       Date:  2015-03-10

6.  Gene therapy of c-myc suppressor FUSE-binding protein-interacting repressor by Sendai virus delivery prevents tracheal stenosis.

Authors:  Daisuke Mizokami; Koji Araki; Nobuaki Tanaka; Hiroshi Suzuki; Masayuki Tomifuji; Taku Yamashita; Yasuji Ueda; Hideaki Shimada; Kazuyuki Matsushita; Akihiro Shiotani
Journal:  PLoS One       Date:  2015-01-08       Impact factor: 3.240

Review 7.  Targeted Gene Delivery Therapies for Cervical Cancer.

Authors:  Ángela Áyen; Yaiza Jiménez Martínez; Houria Boulaiz
Journal:  Cancers (Basel)       Date:  2020-05-21       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.